FDX 350 Brain Check Ultra

Looking after cognitive health has never been so important. According to the Alzheimer’s Society, there are almost a million people with dementia in the UK with projected figures estimating the total will rise to 1.6 million by 2040.  While Alzheimer's disease is incompletely defined, studies have implicated metabolic abnormalities such as insulin resistance, hormonal deficiencies, and hyper-homocysteinemia as potential contributing factors, and Dr Bredesen’s work argues that optimising metabolic parameters has yielded cognitive improvement in both symptomatic and asymptomatic individuals.  Bredesen’s research suggests that Alzheimer’s disease results from an imbalance in the brain’s neuroplasticity signalling thanks to a series of negative assaults on the body that lead to a downsizing of the brain’s ability and a subsequent cognitive decline.   Bredesen has identified 36 factors including metabolic derangement, poor nutrient status, and exposure to viruses that can trigger “downsizing” in the brain and the protocol employs a number of techniques to address those factors including a ketogenic-style Mediterranean diet, brain training, blood tests and a personalised supplementation regime. At FunctionalDX we have compiled Brain Check Ultra which reviews the key biomarkers that are identified by Bredesen to have the most influence on neurological function. They consider the five key areas;

• Insulin resistance
• Inflammation and infections
• Hormone, nutrient, and trophic factor optimisation
• Toxins: chemical, biological, and physical
• Restoration and protection of lost synapses

This is combined with our FDX extensive reporting and interpretation to provide the most in depth analysis of 13 body systems, 7 accessory systems, 7 macro systems, 14 nutrient assessments and more than 40 clinical dysfunction assessments.